A new four pillar-based strategy of HF management asks what underlying mechanisms allow one of its component-sodium-glucose co-transporter-2 (SGLT2) inhibitors to reduce mortality and hospitalization for HF independently from T2DM presence and whether old circulating biomarkers such as NPs can be used to predict HF in T2DM patients treated with SGLT2 inhibitors [15]. Here, SLC5A2 is linked to type 2 diabetes mellitus.